Id Biomedical Corporation of Quebec

Cambrios Film Solutions Corporation

Cambrios Technologies Corporation

David Hugh Jones

George H Lowell

David S Burt

Clement Rioux

Florian Pschenitzka

Michael A Spaid

Jeffrey A Wolk

Xina Quan

Gregory Lee White

Joseph J Zimmermann

Kirkor Torossian

Louis F Fries, Iii

Martin Plante

Composite transparent conductors are described, which comprise a primary conductive medium based on metal nanowires and a secondary conductive medium based on a continuous conductive film.

Composite transparent conductors and methods of forming the same

Methods for making and using therapeutic formulations of Proteosome-based immunoactive compositions are provided. The immunogenic compositions, which include Proteosomes and liposaccharides, may be used to elicit or enhance a nonspecific innate immune response to, for example, treat or prevent infectious disease. In addition, after activating the innate immune system, immunogenic compositions further containing an antigen may be used to elicit a specific adaptive immune response. Furthermore, provided are compositions capable of altering hyperreactive responses or inflammatory immune responses, such as allergic reactions. Such compositions may be used as a prophylactic, or in various clinical settings to treat or prevent infectious disease (such as parasite, fungal, bacterial or viral infections), or to alter inappropriate inflammatory immune responses (such as allergic reactions or asthma).

Compositions and methods for activating innate and allergic immunity

An adjuvant complex composed of bacterial outer membrane protein proteosomes complexed to bacterial liposaccharide is prepared to contain the component parts under a variety of conditions. The complex can be formulated with antigenic material to form immunogenic compositions, vaccines and immunotherapeutics. An induced immune response includes protective antibodies and/or type 1 cytokines is shown for a variety of protocols.

Proteosome-liposaccharide vaccine adjuvant

Improved forms of vaccines which comprise proteosomes and protein antigens are described. Vaccines which contain influenza HA as the antigen are used for illustration as to demonstrate efficacy. Improvements in the preparation of the vaccines themselves and the proteosome component are also included.

Proteosome influenza vaccine

Growing community of inventors

Mountain View, CA, United States of America

David Hugh Jones